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The evaluation of treatment response in patients with metastatic colorectal cancer (mCRC) is estimated by the Response Evaluation Criteria in Solid Tumors (RECIST) as a binary all‐or‐none measurement to assess the potential advantages of tumor shrinkage and to serve as a surrogate for survival benefits.[1](#cas13023-bib-0001){ref-type="ref"} Recently, the assessment of quantitative linear measurements, such as early tumor shrinkage (ETS) and depth of response (DpR), have been highlighted to better explain the actual status of tumor regression or dynamics in response to treatment, particularly with anti‐EGFR antibodies.

Retrospective analyses of several clinical trials have indicated that ETS, which is usually defined as percent tumor shrinkage at 6--8 weeks compared with baseline, was predictive of survival outcomes in several regimens for mCRC, including irinotecan plus cetuximab in the BOND trial, irinotecan with fluorouracil and folinic acid (FOLFIRI) plus cetuximab in the CRYSTAL trial, oxaliplatin with fluorouracil and folinic acid (FOLFOX) plus cetuximab in the OPUS trial, and FOLFOX plus panitumumab in the PRIME trial.[2](#cas13023-bib-0002){ref-type="ref"}, [3](#cas13023-bib-0003){ref-type="ref"}, [4](#cas13023-bib-0004){ref-type="ref"} Retrospective analyses have also shown that DpR, which is defined as the ratio of tumor shrinkage at nadir relative to baseline, was significantly associated with post‐progression survival in the CRYSTAL and OPUS trials.[5](#cas13023-bib-0005){ref-type="ref"} These findings suggest that quantitative analysis of tumor shrinkage could be relevant to survival outcomes in patients treated with anti‐epidermal growth factor receptor (EGFR) agents.

In contrast, the significance of tumor shrinkage on survival outcomes has been equivocal in therapies using the anti‐angiogenic agent bevacizumab. Analyses of the AVF2107 and N9741 trials, involving patients with mCRC receiving first‐line bevacizumab‐containing regimens, suggested that the objective response rate was not a predictor of survival outcomes.[6](#cas13023-bib-0006){ref-type="ref"} Furthermore, overall survival (OS) and progression‐free survival (PFS) did not differ significantly between patients who achieved stable disease as the best response and patients who showed an objective response.[6](#cas13023-bib-0006){ref-type="ref"} A limited number of studies focused on the relevance of ETS and DpR in patients receiving bevacizumab‐based therapy. The results of the FIRE‐3 trial, which compared first‐line FOLFIRI plus either cetuximab or bevacizumab, showed that a higher percentage of patients in the cetuximab arm compared to the bevacizumab arm achieved ETS (68.2% *vs*. 49.1%, *P* = 0.0005) and that median DpR was significantly higher in the cetuximab than in the bevacizumab arm (48.9% *vs*. 32.2%, *P* \< 0.0001).[7](#cas13023-bib-0007){ref-type="ref"} Furthermore, retrospective comparison of second‐line therapy with FOLFIRI plus either cetuximab or bevacizumab showed a statistically significant positive correlation between DpR and OS in the cetuximab arm but not in the bevacizumab arm.[8](#cas13023-bib-0008){ref-type="ref"} These results suggest that assessments of tumor shrinkage based on both binary qualitative and linear quantitative parameters may be insufficient for predicting long‐term survival outcomes in individual patients, at least for those patients receiving bevacizumab‐based chemotherapy.

With the goal of finding new surrogate makers to evaluate the impact of bevacizumab on long‐term survival outcome, we have developed a marker called the two‐dimensional response (2‐DR), which was designed along the new concept of combining the parameters of tumor shrinkage with time factors.

Materials and Methods {#cas13023-sec-0002}
=====================

Study design and setting {#cas13023-sec-0003}
------------------------

This retrospective analysis was undertaken to establish and validate the 2‐DR model as a new surrogate measurement for OS in two independent cohorts, a learning cohort and a validation cohort. In total, 99 patients treated with first‐line regimens containing bevacizumab and oxaliplatin were analyzed.

The learning cohort consisted of 47 patients who participated in the multicenter, single‐armed phase II clinical trial of the Chubu Clinical Oncology Group (CCOG)‐0801 (UMIN trial no. 000006818).[9](#cas13023-bib-0009){ref-type="ref"} Patients were treated with bevacizumab (5 mg/kg) plus FOLFOX, consisting of 85 mg/m^2^ oxaliplatin and 200 mg/m^2^ folinic acid, followed by a bolus infusion of 400 mg/m^2^ fluorouracil and a subsequent continuous infusion of 2400 mg/m^2^ fluorouracil, repeated every 2 weeks. After a median follow‐up period of 55.4 months, 46 disease progressions (97.9%) and 37 deaths (78.7%) occurred in the 47 enrolled patients. Using this cohort, the modified 2‐DR model was established and validated internally. The validation cohort consisted of 52 patients who participated in the CCOG‐0902 trial (UMIN trial no. 000006478).[10](#cas13023-bib-0010){ref-type="ref"} Patients were treated with 7.5 mg/kg bevacizumab plus CapeOX, consisting of 130 mg/m^2^ oxaliplatin on day 1 and oral capecitabine (1000 mg/m^2^ twice daily) for 14 days, followed by a 7‐day treatment‐free interval, with the regimen repeated every 3 weeks; these treatments were followed by maintenance therapy with capecitabine plus bevacizumab. After a median follow‐up period of 49.5 months, 49 disease progressions (94.2%) and 35 deaths (67.3%) occurred in the 52 enrolled patients. The model performance was externally validated in this cohort.

The end‐points of both the trials included: (i) overall response rate, defined as the proportion of patients achieving a best response of complete response or partial response; (ii) disease control rate, defined as the proportion of patients who achieved a best response of complete response, partial response, or stable disease; (iii) PFS, defined as the time from the date therapy was initiated to the date of disease progression or death from any cause; and (iv) OS, defined as the time from the date that therapy was initiated to the date of death from to any cause. Tumor size was assessed at baseline and every 8 weeks thereafter according to RECIST version 1.1.

The study protocol was approved by the institutional review board of each participating institution. Informed consent was waived owing to the retrospective design of this study.

Surrogate measurements of OS {#cas13023-sec-0004}
----------------------------

Early tumor shrinkage and DpR were defined as the ratio of tumor shrinkage observed at 8 weeks after treatment initiation and nadir to baseline, which was expressed as a percentage.

The 2‐DR model was designed as a new concept that combined the parameters of tumor shrinkage with time factors. The previously developed 2‐DR model was defined as the area enclosed by coordinate points, including ETS at 8 weeks, DpR at nadir, and a 20% increase over nadir at disease progression (Fig. [1](#cas13023-fig-0001){ref-type="fig"}).[11](#cas13023-bib-0011){ref-type="ref"} In this study, the 2‐DR was refined as a modified model whose variables were weighted by the contribution rate (CR^variable^) to OS in the learning phase. The modified 2‐DR value was calculated as follows: $$\begin{array}{cl}
{Modified} & {2 - \text{DR}} \\
 & {= \left\lbrack {} \right.{(0.5\, \times \,\text{TTR}\, \times \,\text{CR}^{TTR})} + {(0.9\, \times \,\text{TTP}\, \times \,\text{CR}^{TTP})}} \\
 & {- {(4\, \times \,\text{CR}^{TTP})}\rbrack\, \times \,\left\lbrack {} \right.{(\text{DpR}\, \times \,\text{CR}^{DpR})}} \\
 & {+ {(0.5\, \times \,\text{TTR}\, \times \,\text{CR}^{TTR}\, \times \,\text{ETS}\, \times \,\text{CR}^{ETS})}\rbrack} \\
\end{array}$$

![Model of the two‐dimensional response (2‐DR), developed as a surrogate marker for overall survival in patients with metastatic colorectal cancer. The 2‐DR was defined as the area enclosed by the coordinate points including early tumor shrinkage (ETS) at 8 weeks, depth of response (DpR) at the nadir, and 20% increase over nadir at disease progression.](CAS-107-1492-g001){#cas13023-fig-0001}

where time to best response (TTR) is the time from initiation of therapy to maximum tumor shrinkage and time to progression (TTP) is the time from the date of maximum tumor shrinkage to 20% increase over nadir.

Statistical analysis {#cas13023-sec-0005}
--------------------

Differences in the characteristics of cohorts were analyzed using the χ^2^‐test for categorical variables and the Mann--Whitney *U*‐test for continuous variables. Spearman\'s rank correlation coefficient was used to assess the correlation between each surrogate end‐point and OS. The percent contribution of each parameter was calculated as the square of Spearman\'s correlation coefficient with OS. Loess smoothing curves with 70% of fit points were used to analyze the functional relationship between each measurement and OS. The concordance index (C‐index) and calibration curves were compared with actual observed survival probability to determine the performance of the established model. Receiver--operating characteristic (ROC) curve analysis was used to assess the optimal cut‐off value for 2‐DR; the area under the ROC curve was also calculated. The cut‐off values for ETS and DpR were defined in accordance with previous reports as 20%[3](#cas13023-bib-0003){ref-type="ref"}, [4](#cas13023-bib-0004){ref-type="ref"}, [12](#cas13023-bib-0012){ref-type="ref"}, [13](#cas13023-bib-0013){ref-type="ref"} and 30%,[8](#cas13023-bib-0008){ref-type="ref"} respectively. Survival curves were estimated using the Kaplan--Meier method and compared using the log--rank test. After baseline characteristics and other outcome measures were corrected for, univariate and multivariate analyses of OS were carried out using a Cox proportional hazards model to determine whether 2‐DR was an independent prognostic factor for OS. *P*‐values below 0.05 were considered statistically significant. Statistical analyses were carried out using [spss]{.smallcaps} statistical package version 23 (SPSS, Chicago, IL, USA) and R version 3.1.3 (The R Foundation, <http://www.r-project.org/>).

Results {#cas13023-sec-0006}
=======

Baseline characteristics and treatment status {#cas13023-sec-0007}
---------------------------------------------

The learning and validation cohorts consisted of 99 patients total; the baseline characteristics of the two cohorts were comparable (Table [1](#cas13023-tbl-0001){ref-type="table-wrap"}). Treatment status, including total dose of key drugs and post‐progression treatments, did not differ significantly between these cohorts.

###### 

Patient characteristics and treatment statuses in two independent cohorts of patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab

  Variable                             Learning cohort (*n *= 47)   Validation cohort (*n *= 52)   *P*‐value          
  ------------------------------------ ---------------------------- ------------------------------ ----------- ------ -------
  Patient characteristics                                                                                             
  Age, years                                                                                                          
  Median (range)                       63 (40--74)                  66 (40--80)                    0.091              
  Sex                                                                                                                 
  Male                                 31                           66.0                           31          59.6   0.540
  Female                               16                           34.0                           21          40.4   
  Performance status, WHO                                                                                             
  0                                    29                           61.7                           38          73.1   0.284
  1                                    18                           38.3                           14          26.9   
  Primary site                                                                                                        
  Colon                                31                           66.0                           28          53.8   0.305
  Rectum                               16                           34.0                           24          46.2   
  Number of metastatic sites                                                                                          
  1                                    33                           70.2                           37          71.2   1.000
  \>1                                  14                           29.8                           15          28.8   
  Metastatic site                                                                                                     
  Liver                                22                           46.8                           30          57.7   0.317
  Liver only                           12                           25.5                           16          30.8   0.657
  Lung                                 21                           44.7                           20          38.5   0.547
  Peritoneum                           3                            6.4                            9           9.6    0.127
  Lymph nodes                          10                           21.3                           5           17.3   0.160
  Tumor diameter at baseline, mm                                                                                      
  Median (range)                       50.0 (5.0--946.0)            46.5 (9.9--200.0)              0.768              
  KRAS status                                                                                                         
  Wild type                            18/35                        51.4                           24/41       58.5   0.859
  Mutant type                          17/35                        48.6                           17/41       41.5   
  Treatment status                                                                                                    
  Total dose of oxaliplatin, mg                                                                                       
  Median (range)                       1178 (262--3927)             1052 (470--4346)               0.391              
  Total dose of bevacizumab, mg                                                                                       
  Median (range)                       3002 (500--10401)            2400 (960--9000)               0.864              
  Treatment after first‐line therapy                                                                                  
  Second‐line therapy                  42                           89.4                           46          88.5   1.000
  Anti‐EGFR agents                     14                           29.8                           17          32.7   0.830
  Bevacizumab (BBP)                    33                           70.2                           35          67.3   0.830
  Resection of metastasis              7                            14.9                           8           15.4   1.000

BBP, bevacizumab beyond progression; EGFR, epidermal growth factor receptor.

John Wiley & Sons, Ltd

Survival outcomes and surrogate measures of OS {#cas13023-sec-0008}
----------------------------------------------

The median PFS was 11.3 months (95% confidence interval \[CI\], 8.7--13.9 months) in the learning cohort and 12.4 months (95% CI, 10.0--14.8 months) in the validation cohort (hazard ratio, 1.025; 95% CI, 0.683--1.538; *P* = 0.905). The median OS was 30.0 months (95% CI, 27.8--32.2 months) in the learning cohort and 30.6 months (95% CI, 27.9--33.3 months) in the validation cohort (hazard ratio, 0.756; 95% CI, 0.471--1.214; *P* = 0.248). Surrogate measures of OS, including overall response rate according to RECIST version 1.1 criteria, ETS, and DpR, are presented in Table [2](#cas13023-tbl-0002){ref-type="table-wrap"}. No significant differences in survival outcomes or surrogate measures were found between the learning and validation cohorts.

###### 

Distribution of surrogate measurements for overall survival in two independent cohorts of patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab

  Variable             Learning cohort (*n *= 47)   Validation cohort (*n *= 52)   *P*‐value          
  -------------------- ---------------------------- ------------------------------ ----------- ------ -------
  RECICT response                                                                                     
  Objective response   26                           55.3                           31          59.6   0.841
  Disease control      42                           89.4                           49          94.2   0.472
  ETS, %                                                                                              
  Median (range)       22.7 (−33.3--71.5)           29.6 (−71.4--76.0)             0.196              
  ≥20%                 25                           53.2                           36          69.2   0.147
  DpR, %                                                                                              
  Median (range)       31.3 (−33.3--100.0)          35.8 (−71.4--100.0)            0.651              
  ≥30%                 27                           57.4                           32          61.5   0.842
  2‐DR                                                                                                
  Median (range)       25.0 (−9.8--328.9)           36.7 (−13.9--242.1)            0.563              
  ≥42.5                17                           36.2                           24          46.2   0.414

2‐DR, two‐dimensional response; DpR, depth of response; ETS, early tumor shrinkage; RECIST, Response Evaluation Criteria in Solid Tumors.

John Wiley & Sons, Ltd

Derivation of the 2‐DR model {#cas13023-sec-0009}
----------------------------

Spearman\'s rank correlation analysis showed that the degrees of correlation between OS and the parameters ETS, DpR, TTR, and TTP were 0.28, 0.30, 0.13, and 0.64, respectively, in the learning cohort and 0.24, 0.30, 0.07, and 0.65, respectively, in the validation cohort. The contribution of each parameter to OS showed a similar trend in both cohorts. By applying these coefficients in the learning cohort, the contribution rates were calculated as 0.078 for CR^ETS^, 0.089 for CR^DpR^, 0.017 for CR^TTR^, and 0.415 for CR^TTP^.

The performance of the 2‐DR model was assessed by ROC curve analysis; the area under the ROC curve was 0.785 (95% CI, 0.650--0.919; *P* = 0.001) in the learning cohort and 0.817 (95% CI, 0.698--0.936; *P* \< 0.001) in the validation cohort. The ROC curve analysis for predicting OS over 30 months showed that the optimal cut‐off value for 2‐DR was 42.5 (Fig. [1](#cas13023-fig-0001){ref-type="fig"}). Using this cut‐off value, the 2‐DR had positive and negative predictive values of 82.4% and 73.3%, respectively, in the learning cohort, and 70.8% and 78.6%, respectively, in the validation cohort.

Validation of the 2‐DR model {#cas13023-sec-0010}
----------------------------

The 2‐DR model was validated internally in the learning cohort and externally in the validation cohort. Median values of 2‐DR for internal and external validation were 25.0 (range, −9.8 to 328.9) and 36.7 (range, −13.9 to 242.1), respectively. The distribution of 2‐DR is shown in Figure [2](#cas13023-fig-0002){ref-type="fig"}.

![Distribution of the two‐dimensional response (2‐DR), developed as a surrogate marker for overall survival, in patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab. Each plot was characterized according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.](CAS-107-1492-g002){#cas13023-fig-0002}

Spearman\'s correlation coefficients for 2‐DR and OS were 0.593 (*P* \< 0.001) in the learning cohort and 0.661 (*P* \< 0.001) in the validation cohort. The correlation plots of 2‐DR and other surrogate measurements are presented in Figure [3](#cas13023-fig-0003){ref-type="fig"}.

![Correlations between surrogate measures and overall survival in two independent cohorts of patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab. Green and blue dots represent patients in the learning and validation cohorts, respectively. Loess smoothing curves were used to indicate the functional relationship between each parameter and overall survival.](CAS-107-1492-g003){#cas13023-fig-0003}

The C‐indexes of the 2‐DR model in predicting OS were 0.724 (95% CI, 0.623--0.815) in the internal validation and 0.762 (95% CI, 0.651--0.873) in the external validation; the C‐indexes of ETS and DpR were 0.623 (95% CI, 0.504--0.740) and 0.640 (95% CI, 0.525--0.751) in the internal validation and 0.588 (95% CI, 0.477--0.699) and 0.593 (95% CI, 0.482--0.704) in the external validation, respectively.

Overall survival was significantly longer in patients with high 2‐DR values than in patients with low 2‐DR values during the internal validation (37.0 months \[95% CI, 29.8--44.2 months\] *vs*. 24.1 months \[95% CI, 20.4--27.8 months\], *P* \< 0.001) and external validation (41.2 months \[95% CI, 36.6--45.8 months\] *vs*. 20.4 months \[95% CI, 17.4--23.4 months\], *P* \< 0.001) (Fig. [4](#cas13023-fig-0004){ref-type="fig"}). In contrast, the differences in ETS (internal validation, 32.7 months \[95% CI, 29.5--36.0 months\] *vs*. 25.5 months \[95% CI, 21.8--29.2 months\], *P* = 0.121; external validation, 31.6 months \[95% CI, 29.1--34.1 months\] *vs*. 20.5 months \[95% CI, 7.6--33.4 months\], *P* = 0.141) and DpR (internal validation, 31.0 months \[95% CI, 26.8--35.2 months\] *vs*. 25.5 months \[95% CI, 21.3--29.7 months\], *P* = 0.094; external validation, 31.6 months \[95% CI, 22.4--40.8 months\] *vs*. 28.4 months \[95% CI, 19.3--37.6 months\], *P* = 0.431) were not statistically significant in either validation.

![Kaplan--Meier curves for overall survival in patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab, according to the surrogate measures. (a) Early tumor shrinkage. (b) Depth of response. (c) Two‐dimensional response (2‐DR).](CAS-107-1492-g004){#cas13023-fig-0004}

Univariate analyses showed that TTP and 2‐DR were significantly associated with OS. Multivariate analyses showed that 2‐DR was the only independent prognostic factor of OS in both the learning and validation cohorts (Table [3](#cas13023-tbl-0003){ref-type="table-wrap"}).

###### 

Impact of surrogate measurements on overall survival in two independent cohorts of patients with metastatic colorectal cancer who were treated with oxaliplatin‐based chemotherapy plus bevacizumab

  Variables               Internal validation (*n *= 47)   External validation (*n *= 52)                                                        
  ----------------------- -------------------------------- -------------------------------- -------------- --------- ---- ------- -------------- -------
  Univariate analysis                                                                                                                            
  ETS, %                                                                                                                                         
  \<20%                   22                               Ref.                                                      16   Ref.                   
  ≥20%                    25                               0.597                            0.308--1.155   0.126     36   0.578   0.274--1.219   0.150
  DpR, %                                                                                                                                         
  \<30%                   23                               Ref.                                                      27   Ref.                   
  ≥30%                    24                               0.557                            0.289--1.074   0.081     25   0.635   0.308--1.307   0.217
  TTR, weeks                                                                                                                                     
  \<Median                23                               Ref.                                                      25   Ref.                   
  ≥Median                 24                               0.600                            0.306--1.177   0.137     27   1.094   0.561--2.133   0.792
  TTP, weeks                                                                                                                                     
  \<Median                24                               Ref.                                                      26   Ref.                   
  ≥Median                 23                               0.322                            0.161--0.646   0.001     26   0.325   0.163--0.647   0.001
  2‐DR                                                                                                                                           
  \<Cut‐off value         30                               Ref.                                                      28   Ref.                   
  ≥Cut‐off value          17                               0.239                            0.108--0.529   \<0.001   24   0.244   0.110--0.545   0.001
  Multivariate analysis                                                                                                                          
  TTP, weeks                                                                                                                                     
  \<Median                24                               Ref.                                                      26   Ref.                   
  ≥Median                 23                               0.604                            0.265--1.377   0.230     26   0.644   0.255--1.622   0.350
  2‐DR                                                                                                                                           
  \<Cut‐off value         30                               Ref.                                                      28   Ref.                   
  ≥Cut‐off value          17                               0.322                            0.125--0.827   0.019     24   0.334   0.116--0.958   0.041

2‐DR, two‐dimensional response; CI, confidence interval; DpR, depth of response; ETS, early tumor shrinkage; HR, hazard ratio; Ref., reference; TTP, time to progression; TTR, time to response.

John Wiley & Sons, Ltd

Discussion {#cas13023-sec-0011}
==========

This study is the first to evaluate the modified 2‐DR as a new surrogate marker of OS in patients with mCRC. This model was developed and verified in two independent cohorts consisting of patients who participated in phase II trials of first‐line oxaliplatin‐based chemotherapy plus bevacizumab. The correlation between 2‐DR and OS was statistically significant in both internal and external validations. The C‐index showed that this model could predict actually observed survival. Overall was significantly greater in patients with high 2‐DR values than in patients with low 2‐DR values, with a cut‐off of 42.5 being a clear prognostic value in both cohorts.

Linear quantitative parameters, including ETS and DpR, have been shown to be useful in assessing the value of chemotherapy, especially regimens consisting of anti‐EGFR antibodies.[2](#cas13023-bib-0002){ref-type="ref"}, [3](#cas13023-bib-0003){ref-type="ref"}, [4](#cas13023-bib-0004){ref-type="ref"}, [12](#cas13023-bib-0012){ref-type="ref"}, [14](#cas13023-bib-0014){ref-type="ref"} However, in our patients, these parameters showed only weak correlations with long‐term OS. These differences may be owing to differences in the mechanisms of action of bevacizumab and anti‐EGFR agents. Bevacizumab has a cytostatic effect rather than a direct cytotoxic effect, which may be reflected more by disease control than by tumor shrinkage.[6](#cas13023-bib-0006){ref-type="ref"} In addition, the profile of molecules predictive of tumor response and survival might be different in the case of bevacizumab. The levels of vascular endothelial growth factor (VEGF), the molecular target of bevacizumab, have been associated with tumor response, but not with survival. However, upstream promoters of angiogenesis and hypoxia, such as CA9 and HIF‐2α, were significantly associated with survival outcomes.[13](#cas13023-bib-0013){ref-type="ref"}

Moreover, radiologic responses to bevacizumab‐containing regimens in patients with colorectal liver metastasis included not only shrinkage of tumor size but also morphological changes, such as homogeneous low attenuation with a thin and sharply defined tumor interface.[15](#cas13023-bib-0015){ref-type="ref"} The optimal morphologic response correlated significantly with OS.[16](#cas13023-bib-0016){ref-type="ref"} These findings suggest that linear assessments of tumor shrinkage may have limitations in determining the effects of bevacizumab on long‐term survival outcomes.

The 2‐DR model combines parameters of tumor shrinkage with the effects of treatment over time. Of patients with high 2‐DR values, approximately 20% showed minor responses with long‐term stable disease and 60% showed major responses to treatment. These results indicate that 2‐DR may reflect both the cytostatic effects of bevacizumab and the cytotoxic effects of chemotherapy and may act as a surrogate marker of long‐term survival.

The 2‐DR model also considered the contribution of individual parameters because each of these parameters showed different degrees of correlation with OS. Time to progression following best response was strongly correlated with OS, whereas TTR showed only a weak correlation. Early tumor shrinkage and DpR had similar moderate degrees of correlation with OS. These correlations were similar in two independent cohorts of patients treated with bevacizumab‐containing regimens. Although the weight of each parameter on the cytotoxic and targeted agents may differ, the 2‐DR model may be adapted to other regimens by adjusting the contribution rates.

This study has several limitations. First, tumor size and response according to RECIST were not evaluated by central review. Second, the treatment regimens in the learning and validation cohorts differed, although their baseline characteristics, treatment status including total dose and dose intensity of key drugs, and treatment outcomes were comparable. Furthermore, the degree of correlation between each parameter and OS showed a similar trend in both cohorts. Third, the relatively small sample size of this study necessitates confirmation of these results in a larger cohort study. Finally, this model of 2‐DR is too complicated for use in the clinical setting. However, the aim of this report was to propose the concept of combining the parameters of tumor shrinkage with time factors for use primarily in evaluating treatment regimens in clinical trials. In the next phase, efforts will have to be made to establish a simpler surrogate marker for application in the clinical practice setting.

In conclusion, our exploratory analysis of 2‐DR as a new surrogate marker for OS in a pooled data set from two independent cohorts reveals that 2‐DR may predict long‐term survival outcomes in patients with mCRC treated with bevacizumab‐containing regimens.
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